Phase 3 Trial Of ADCETRIS With Modified Chemo Regimen Shows Non-Inferiority With Unprecedented 3-Year Progression Free Survival Of 94.9% Vs Less Tolerable International Standard Of Care In Advanced Classical Hodgkin Lymphoma
Portfolio Pulse from Happy Mohamed
Seagen Inc. announced that a phase 3 trial of ADCETRIS in combination with chemotherapy met its co-primary endpoints of non-inferior efficacy and superior tolerability versus the international standard eBEACOPP therapy in advanced classical Hodgkin lymphoma. The trial showed a 94.9% 3-year progression-free survival rate for patients treated with the ADCETRIS combination.
June 20, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seagen's phase 3 trial of ADCETRIS with chemotherapy met its co-primary endpoints, showing non-inferior efficacy and superior tolerability in advanced classical Hodgkin lymphoma.
The positive results from the phase 3 trial of ADCETRIS in combination with chemotherapy indicate that the treatment is effective and well-tolerated in advanced classical Hodgkin lymphoma patients. This could lead to increased demand for the treatment and potential growth in Seagen's revenues, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100